URGN | Ticker Profile - Titan Protect

URGN

UroGen Pharma Ltd.

Healthcare · Biotechnology · NGM

$26.85

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.4B

Total market value of the company

Trailing P/E

N/A

Forward P/E

20.42

Based on estimated future earnings — lower means cheaper

Rev Growth

+151.6%

Year-over-year revenue change

Profit Margin

-94.8%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$40.00

+49% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 9 analysts covering this stock

About UroGen Pharma Ltd.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

https://www.urogen.com

Country: United States Employees: 298 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.872

Good returns relative to risk taken

Kelly Fraction

0.0715

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.596

Acceptable balance between returns and drawdown risk

Annual Return

47.4%

Historical annualised return based on price data

Max Drawdown

-79.5%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

118

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.59

Significantly more volatile than the market

52W High

$32.37

17% below the year high

52W Low

$3.61

645% above the year low

Avg Volume

876,967

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

14.2%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.74

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

4.69

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

3.87

Like current ratio but excludes inventory — stricter test

Gross Margin

89.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-39.8%

Profit from core operations before interest and tax

Free Cash Flow

$-109,282,248

Negative — the business is spending more than it generates

Revenue (TTM)

$140M

Total revenue over the last 12 months

Net Income

$-133,225,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$45.00

Target Median

$40.00

Target Low

$18.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go